IRIS
PIRISI, Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.397
NA - Nord America 6.559
AS - Asia 1.546
Continente sconosciuto - Info sul continente non disponibili 21
SA - Sud America 18
AF - Africa 13
OC - Oceania 6
Totale 16.560
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.513
IE - Irlanda 2.753
SE - Svezia 1.268
IT - Italia 1.187
DE - Germania 1.041
UA - Ucraina 887
FR - Francia 653
CN - Cina 548
HK - Hong Kong 480
FI - Finlandia 379
IN - India 302
GB - Regno Unito 79
VN - Vietnam 63
CZ - Repubblica Ceca 55
IR - Iran 53
CA - Canada 44
BE - Belgio 38
TR - Turchia 30
EU - Europa 20
KR - Corea 15
RU - Federazione Russa 14
NL - Olanda 11
JP - Giappone 10
PK - Pakistan 10
CL - Cile 8
MY - Malesia 7
PL - Polonia 7
RO - Romania 7
AU - Australia 6
KE - Kenya 6
PH - Filippine 6
CH - Svizzera 4
EG - Egitto 4
ID - Indonesia 4
MO - Macao, regione amministrativa speciale della Cina 4
BR - Brasile 3
GR - Grecia 3
PE - Perù 3
SA - Arabia Saudita 3
SG - Singapore 3
TH - Thailandia 3
AR - Argentina 2
CO - Colombia 2
CU - Cuba 2
IL - Israele 2
IQ - Iraq 2
LI - Liechtenstein 2
LY - Libia 2
NO - Norvegia 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BD - Bangladesh 1
BG - Bulgaria 1
ES - Italia 1
MK - Macedonia 1
PT - Portogallo 1
SN - Senegal 1
Totale 16.560
Salva come PNG Salva come JPEG
Città #
Dublin 2.735
Jacksonville 1.663
Dearborn 737
Chandler 604
Hong Kong 468
Wilmington 432
Princeton 334
Lawrence 333
San Mateo 252
Ann Arbor 241
Novara 241
Beijing 238
Piemonte 216
Ashburn 154
Andover 130
Milan 81
Houston 77
Woodbridge 71
Bremen 65
Dong Ket 60
Boardman 57
Nanjing 56
Turin 53
Hefei 49
Philadelphia 39
Düsseldorf 38
Brussels 36
Helsinki 35
Norwalk 33
Pardubice 32
Kunming 28
Kocaeli 27
Seattle 25
Vercelli 25
Torino 23
Monmouth Junction 20
Mülheim 19
Fairfield 18
Jinan 18
Nanchang 18
Alessandria 17
Strasbourg 17
Ardabil 16
Cassano Magnago 16
Guangzhou 16
Leawood 15
Rome 15
Toronto 14
West Jordan 14
Zanjan 14
České Budějovice 14
Grafing 13
Augusta 12
Chennai 12
Shenyang 10
Fuzhou 9
Odalengo Grande 9
Paris 9
Villa Cortese 9
Zhengzhou 9
Alba 8
Bologna 8
Lancenigo-Villorba 8
Montreal 8
Redwood City 8
Berlin 7
Brescia 7
Frankfurt am Main 7
New York 7
Royal Leamington Spa 7
Sham Shui Po 7
Stankov 7
Suwon 7
Wuhan 7
Nairobi 6
Shanghai 6
Verona 6
Cambridge 5
Hebei 5
Kraków 5
Menlo Park 5
Naples 5
Ningbo 5
Palermo 5
Stresa 5
Vancouver 5
Xian 5
Borgomanero 4
Canegrate 4
Changsha 4
Chengdu 4
Genoa 4
Macao 4
Moncalieri 4
Oleggio 4
Ovada 4
Quzhou 4
San Diego 4
Senigallia 4
Tehran 4
Totale 10.264
Salva come PNG Salva come JPEG
Nome #
Midterm functional sequelae and implications in rehabilitation after COVID19. A cross-sectional study 192
Fatality rate and predictors of mortality in an Italian cohort of hospitalized COVID-19 patients 137
Role of beta-blockers in patients with COPD: current perspective. 110
Testosterone Plasma Concentration is Associated with Insulin Resistance in Male Hypertensive Patients 99
Simple Parameters from Complete Blood Count Predict In-Hospital Mortality in COVID-19 94
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 92
Gas6 as a predictor of esophageal varices in patients affected by hepatitis C virus related-chronic liver disease 92
B2-Lymphocyte responses to oxidative stress-derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) 91
Change over time of COVID-19 hospital presentation in Northern Italy 89
Contribution of Atrial Fibrillation to In-Hospital Mortality in Patients With COVID-19 87
Levosimendan inhibits peroxidation in hepatocytes by modulating apoptosis/autophagy interplay. 84
Gas6/TAM system: A key modulator of the interplay between inflammation and fibrosis 78
Red cell distribution width and platelet count as biomarkers of pulmonary arterial hypertension in patients with connective tissue disorders 78
Antiviral treatment of hepatitis C improves glucose metabolism along the entire spectrum from normal glucose tolerance to diabetes 77
Prediction of serum markers of fibrosis by levels of circulating intercellular adhesion molecule-1 in acute and chronic liver disease 76
Altered glucose metabolism rather than naive type 2 diabetes mellitus (T2DM) is related to vitamin D status in severe obesity. 76
Influence of age on sex-related differences among patients with hepatitis C. 76
Liver infection and COVID-19: the electron microscopy proof and revision of the literature 75
Interferon alpha concentrations in blood and peritoneal fluid during treatment for hepatitis C 73
Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma 73
Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis 73
rs1801253 Gly/Gly carriage in the ADRB1 gene leads to unbalanced cardiac sympathetic modulation as assessed by spectral analysis of heart rate variability 72
Relation among anti-rheumatic drug therapy, CD14(+)CD16(+) blood monocytes and disease activity markers (DAS28 and US7 scores) in rheumatoid arthritis: A pilot study. 72
Acute decompensated heart failure in the emergency department: Identification of early predictors of outcome 70
Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver disease 69
Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease is predicted by circulating levels of adhesion molecules 69
Prediction of jaundice by markers of inflammation in patients with liver disease 68
Reactivity to B cell epitopes within hepatitis C virus core protein and hepatocellular carcinoma 68
17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle 68
Association between rheumatic diseases and cancer: results from a clinical practice cohort study 68
Pattern of emergency department referral during the Covid-19 outbreak in Italy 68
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19 68
High prevalence of infection with hapatitis G virus in patients with hepatic and extrahepatic malignancies 67
Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients 67
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients 67
Association between red cell distribution width and response to methotrexate in rheumatoid arthritis 67
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 65
Role of positron emission tomography in the assessment of disease burden and risk of relapse in patients affected by giant cell arteritis 65
Inflammatory markers predict insulin sensitivity in active rheumatoid arthritis but not in psoriatic arthritis 65
Improvement of insulin sensitivity in diabetic and non diabetic patients with chronic hepatitis C treated with direct antiviral agents 65
(Letter) Membranoproliferative glomerulonephritis associated with Hepatitis C infection with no evidence of liver disease 64
Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. 64
Ultrasound-assessed visceral fat and associations with glucose homeostasis and cardiovascular risk in clinical practice 64
Genistein and 17β-Estradiol Protect Hepatocytes from Fatty Degeneration by Mechanisms Involving Mitochondria, Inflammasome and Kinases Activation 64
Evaluation of circulating activin-A as a serum marker of hepatocellular carcinoma 63
Diagnostic value of FibroTest with normal serum aminotransferases 63
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 63
Analysis of beta1 and beta2-adrenergic receptors polymorphism in patients with apical ballooning cardiomyopathy 63
Severity of nonalcoholic fatty liver disease in type 2 diabetes mellitus: Relationship between nongenetic factors and PNPLA3/HSD17B13 polymorphisms 63
Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge 63
One-Year Follow up of Noninvasive Respiratory Support in General Wards 62
Intensity of inflammatory damage and serum lipid peroxide concentrations in liver disease 62
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 62
Natural history and risk stratification of patients undergoing non-invasive ventilation in a non-ICU setting for severe COPD exacerbations 62
Patterns of infections in older patients acutely admitted to medical wards: data from the REPOSI register 62
Outcomes of COVID-19 patients treated with continuous positive airway pressure outside ICU 62
Hypeglycaemia-induced thrombin formation in Diabetes. The possible role of oxydative stress 61
Evidence against a direct role played by transfusion-transmitted virus infection in causing hepatic or hematologic manifestations 61
Endotoxin priming and liver damage by experimental duodenal obstruction in the rat 61
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 61
Increased plasma levels of Gas6 and its soluble tyrosine kinase receptors Mer and Axl are associated with immunological activity and severity of lupus nephritis 61
Prognostic value of serum alpha-1-antitrypsin in hepatocellular carcinoma 61
Endotoxin priming worsens acute reflux pancreatitis in the rat 60
Circulating intercellular adhesion molecule-1 (clCAM-1) concentration in liver disease 60
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 60
Peroxisome proliferator-activated receptor-gamma expression in monocytes/macrophages from rheumatoid arthritis patients: relation to disease activity and therapy efficacy--a pilot study 60
Is cholecalciferol a potential disease modifying anti-rheumatic drug for the management of rheumatoid arthritis? 60
Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment 60
Thrombocytopenia in chronic liver disease corrected by erithropoietin treatment 59
Impaired glucose metabolism in hypertensive patients with/without the metabolic syndrome. 59
4. Association between release of tumor necrosis factor and response to interferon therapy in chronic hepatitis C 59
Fibrinogen plasma levels as a marker of thrombin activation: new insights on the role of fibrinogen as a cardiovascular risk factor 59
Oxidative Stress in Non-Alcoholic Fatty Liver Disease 59
Immune suppressive treatment of Berger disease 58
Evidence for a multifactorial control of serum erythropoietin concentration in liver disease 58
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C 58
Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. 58
Fibrosis Progression in HCV Carriers with Mild Hepatitis Who Possess the High-Repetition Variant of the DRD4 Gene, a Genetic Marker for Binge-Drinking and Risk-Seeking Behavior: A Longitudinal Study. 58
Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of the AST to platelet ratio index 58
Long-term remission of corticosteroid- and cyclophosphamide-resistant Henoch-Schönlein purpura with rituximab 58
Gas6 as a putative noninvasive biomarker of hepatic fibrosis 58
Cardiac dysfunction as an early predictor of portal hypertension in chronic hepatitis C 58
Can apical ballooning cardiomyopathy and anterior STEMI be differentiated based on β1 and β2-adrenergic receptors polymorphisms? 58
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 58
Emodinamica sistemica ed emodinamica renale 57
Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases 57
Increased serum phospholipase A2 activity in advanced chronic liver disease as an expression in the acute phase response 57
Letter. Activation of the endogenous interferon sustem, expression of interferon-alpha receptors, and response to interferon therapy in chronic hepatitis C 57
Influence of angiotensin-converting enzyme I/D gene polymorphism on clinical and histological correlates of chronic hepatitis C 57
APOLIPOPROTEIN E GENOTYPES MODULATE FIBROSIS PROGRESSION IN PATIENTS WITH CHRONIC HEPATITIS C AND PERSISTENTLY NORMAL TRANSAMINASES 57
Interplay of PNPLA3 and HSD17B13 Variants in Modulating the Risk of Hepatocellular Carcinoma among Hepatitis C Patients 57
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study 57
Changes in blood lipid composition and response to Interferon treatment in Chronic Hepatitis C 56
Diagnostic usefulness of acute phase protein measurement in hepatocellular carcinoma 56
Fatal human pulmonary infection caused by an Angiostrongylus-like nematode 56
Immunosoppressive treatment for idiopathic nephrotic syndrome with corticosteroids and cyclophosphamide 56
IL28B Polymorphism, Blood Interferon-alpha Concentration, and Disease Stage of HCV Mono-infected and HCV-HIV Co-infected Patients. 56
Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C 56
Significato e valore diagnostico dei sintomi e degli esami di laboratorio 56
AORTIC INVOLVEMENT IN A RETROSPECTIVE COHORT OF LARGE VESSEL VASCULITIS PATIENTS 56
Totale 6.779
Salva come PNG Salva come JPEG
Categoria #
all - tutte 82.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 82.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20198 0 0 0 0 0 0 0 0 0 0 1 7
2019/20203.524 19 62 334 8 560 456 652 192 415 480 323 23
2020/20212.295 299 7 303 14 327 97 318 50 327 77 364 112
2021/20222.292 101 58 459 229 113 28 168 80 196 104 286 470
2022/20235.506 503 221 277 151 299 446 166 229 2.836 34 223 121
2023/20241.970 140 344 150 76 392 74 484 134 54 86 36 0
Totale 17.136